Get started
Author

Michael Sangmin Lee

Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).
2018 · Stacey Stein, Michael J. Pishvaian, et al. · Journal of Clinical Oncology · 112
Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer.
2022 · Van K. Morris, Christine Megerdichian Parseghian, et al. · Journal of Clinical Oncology · 76
Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS/NRAS/BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
2021 · Michael Sangmin Lee, Patrick J. Loehrer, et al. · Journal of Clinical Oncology · 43
Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRASG12D siRNA in patients with metastatic pancreatic cancer harboring a KRASG12D mutation.
2022 · Rishi Surana, Valerie S. LeBleu, et al. · Journal of Clinical Oncology · 41
Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer
2020 · Shailesh M. Advani, Michael D. Swartz, et al. · Clinical Colorectal Cancer · 34
Longitudinal and personalized detection of circulating tumor DNA (ctDNA) for monitoring efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC).
2020 · Chih-Hung Hsu, Shan Lu, et al. · Journal of Clinical Oncology · 34
Association of primary (1°) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor (αEGFR) therapy.
2016 · Michael Sangmin Lee, Shailesh M Advani, et al. · Journal of Clinical Oncology · 26
Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), BRAFV600E metastatic colorectal cancer.
2022 · Van K. Morris, Christine Megerdichian Parseghian, et al. · Journal of Clinical Oncology · 17
Addition of metastasis-directed therapy to standard-of-care systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): Results of a multicenter, randomized phase II trial.
2024 · Ethan B. Ludmir, Alexander Dean Sherry, et al. · Journal of Clinical Oncology · 15
PDF
Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program.
2023 · Arvind Dasari, Alisha Heather Bent, et al. · Journal of Clinical Oncology · 11
A randomized phase II trial of MEK and CDK4/6 inhibitors vesus tipiracil/trifluridine (TAS-102) in metastatic KRAS/NRAS mutant (mut) colorectal cancer (CRC).
2022 · Michael Sangmin Lee, Tyler J. Zemla, et al. · Journal of Clinical Oncology · 8
A phase Ib trial of ERK inhibition with ulixertinib combined with palbociclib in patients (Pts) with advanced solid tumors.
2021 · Alison L. Raybould, Brian Burgess, et al. · Journal of Clinical Oncology · 8
Safety and efficacy of neoadjuvant pembrolizumab in mismatch repair deficient localized/locally advanced solid tumors.
2021 · Kaysia Ludford, Kanwal Pratap Singh Raghav, et al. · Journal of Clinical Oncology · 8
Characterization of the number and site of APC mutations in sporadic colorectal cancer.
2017 · Ranjit Joseph, Paul Little, et al. · Journal of Clinical Oncology · 7
Phase I study of hydroxychloroquine plus binimetinib in patients with metastatic pancreatic cancer (the HOPE trial).
2022 · Rishi Surana, J. Jack Lee, et al. · Journal of Clinical Oncology · 5
Prognostic role of systemic inflammatory markers in patients with metastatic MSI-h/dMMR colorectal cancer receiving immunotherapy.
2022 · Deepak Bhamidipati, Kanwal Pratap Singh Raghav, et al. · Journal of Clinical Oncology · 4
Phase Ib/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer.
2017 · Andrew Wang, Autumn Jackson McRee, et al. · Journal of Clinical Oncology · 4
An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab plus bevacizumab for the treatment of patients with advanced colorectal carcinoma.
2024 · Heinz-Josef Lenz, Ashwin Somasundaram, et al. · Journal of Clinical Oncology · 3
PDF
Frequency and oncologic outcomes of KRAS mutations in circulating tumor DNA of patients with pancreatic ductal adenocarcinoma.
2024 · Mahmoud M.G. Yousef, Mark W. Hurd, et al. · Journal of Clinical Oncology · 3
PDF
Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.
2022 · Robin Kate Kelley, Eric Van Cutsem, et al. · Journal of Clinical Oncology · 3
Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer.
2014 · Michael Sangmin Lee, Michael J. Overman, et al. · Journal of Clinical Oncology · 3
Phase I/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF V600E metastatic colorectal cancer following progression on prior BRAF+EGFR targeted therapies.
2025 · Kelsey Pan, Yunyu Baig, et al. · Journal of Clinical Oncology · 2
PDF
Natural history and patterns of progression for dMMR/MSI-H colorectal cancer treated with immune checkpoint blockade: A single center retrospective analysis.
2024 · Victoria Higbie, Preksha Shah, et al. · Journal of Clinical Oncology · 2
PDF
Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers).
2023 · Michael Sangmin Lee, Aparna Raj Parikh, et al. · Journal of Clinical Oncology · 2
Clinical outcomes following termination of immunotherapy due to long-term benefit in MSI-H colorectal cancer.
2022 · Kristen Simmons, Bryan K. Kee, et al. · Journal of Clinical Oncology · 2
Works count: 48
Citation count: 481
H-index: 10
I10-index: 10
Year
Topic
Type